The role of alemtuzumab in the development of secondary autoimmunity in multiple sclerosis: a systematic review
Abstract Background Secondary autoimmune disease (SAID) in the context of alemtuzumab treatment is one of the main safety concerns that may arise following administration in people with multiple sclerosis (pwMS). Contributing factors underlying this adverse event are not well understood. The purpose...
Gorde:
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2024-11-01
|
| Saila: | Journal of Neuroinflammation |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s12974-024-03263-9 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|